Philip Gutry

Phil Gutry joined MPM’s San Francisco office in 2011. He serves on the board of Amphivena Therapeutics and has been involved in MPM’s investments in Astute Medical, Vascular Pharmaceuticals, and CoStim Pharmaceuticals. He previously worked for five years in Corporate Development at Gilead sciences where he focused on M&A and licensing in antiviral, respiratory, liver disease, and oncology. Prior to Gilead, Phil was a Principal at Riverside Partners where he spent six years focused on private equity investments in life science instrumentation, diagnostics, and medical products companies. Phil began his career with The Wilkerson Group, a healthcare focused consulting firm. Phil holds an M.B.A. from The Wharton School and an A.B. from Dartmouth College.